-
Weight-loss medications tamp down hunger — often dramatically — causing some people to lose the pleasure of communing over food at a festive family meal.
-
Many welcome what they say is greater control over what they eat. “I don’t care about the bread as much. I still eat what I enjoy,” says one Tampa area woman who lost more than 200 pounds taking Mounjaro.
-
Wegovy is a high-dose version of the diabetes treatment Ozempic. The international trial showed the weekly injections prevented heart attacks, strokes and heart-related deaths.
-
Doctors and patients around the country say getting on the high-demand, injectable drugs requires persistence and a fair amount of luck.
-
The drugs can slow digestion so much that it puts patients at increased risk for pulmonary aspiration, which can cause dangerous lung damage, infections and even death, says one anesthesiologist.
-
Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.
-
Interest drops if users potentially have to deal with weekly injections, lack of insurance coverage or a need to continue the medications indefinitely to avoid regaining weight.
-
New research shows high-dose oral versions of the medication in the blockbuster drugs Ozepmic and Wegovy may work as well as the popular injections — even in hard-to-treat people with diabetes.
-
A small but growing group of young teens are turning to drastic treatments to lose large amounts of weight, things like body-altering surgery and new drugs that rewire metabolism.
-
Agency officials say they have received reports of problems after patients used versions of semaglutide, the active ingredient in the brand-name medications, that have been compounded or mixed in pharmacies.